Klin Farmakol Farm. 2009;23(1):30-34

Viral hepatitis C

prof. MUDr. Petr Husa CSc

Klinika infekčních chorob, FN Brno

Since the early 21st century, the standard treatment for chronic infection with the hepatitis C virus (HCV) has been the combination of

pegylated interferon alpha and ribavirin. However, new ways of how to make the most of the therapeutic potential of these drugs are

being sought. Based on an analysis of baseline parameters, relating to both the virus and the patient, and on monitoring viral kinetics

in the early stages of antiviral therapy, the required duration of treatment is tailored specifically to fit an individual patient‘s needs.

Repeated treatment with pegylated interferon and ribavirin results in achieving a sustained virological response in a proportion

of patients who had been unsuccessfully treated with these drugs in the past. Clinical trials in various phases test the efficacy and safety

of Specifically Targeted Antiviral Therapy for hepatitis C (C – STAT-C).

Keywords: viral hepatitis C, pegylated interferon alpha, ribavirin, STAT-C.

Published: May 1, 2009  Show citation